Volume 62, Issue 5, Pages (November 2002)

Slides:



Advertisements
Similar presentations
Volume 68, Issue 5, Pages (November 2005)
Advertisements

Volume 65, Issue 6, Pages (June 2004)
Beta blockers in the management of chronic kidney disease
Dylan Burger, Adeera Levin  Kidney International 
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Volume 79, Issue 9, Pages (May 2011)
Volume 83, Issue 3, Pages (March 2013)
Peter Libby, Andrew H. Lichtman, Göran K. Hansson  Immunity 
Volume 68, Issue 5, Pages (November 2005)
C-reactive protein and dialysis access
Figure 1 Innate immune responses in atherosclerosis
Volume 66, Issue 1, Pages (July 2004)
Determinants of Plasma Adiponectin Levels in Nondiabetic Subjects With Moderate to Severe Chronic Kidney Disease  Luis F. Ramos, MD, Ayumi Shintani, PhD,
Atheroma: more than mush
C-reactive protein and dialysis access
John P. Middleton, Patrick H. Pun  Kidney International 
Volume 85, Issue 3, Pages (March 2014)
Volume 61, Issue 1, Pages (January 2002)
Inflammation: The classic double-edged sword
Oxidative Modification of Leukocyte Adhesion
Volume 70, Issue 11, Pages (December 2006)
Volume 67, Issue 1, Pages (January 2005)
J. Himmelfarb, T.A. Ikizler  Kidney International 
Margus Annuk, Mihkel Zilmer, Bengt Fellström
End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?  Mustafa Arici, John Walls  Kidney International 
Bisphosphonate safety and efficacy in chronic kidney disease
Oxidative stress, AGE, and atherosclerosis
Vitamin D receptor: A highly versatile nuclear receptor
Volume 70, Issue 12, Pages (December 2006)
Relationship between methylmalonic acid and cobalamin in uremia
Joel D. Kopple, Kamyar Kalantar-Zadeh, Rajnish Mehrotra 
Volume 65, Issue 6, Pages (June 2004)
Volume 73, Issue 12, Pages (June 2008)
Macrophages and hypoxia in human chronic kidney disease
Volume 67, Pages S51-S58 (June 2005)
Endothelial dysfunction and inflammation: What is the link?
Disaster nephrology: crush injury and beyond
Volume 76, Issue 4, Pages (August 2009)
Volume 62, Issue 5, Pages (November 2002)
Kidney failure and the gut: p-cresol and the dangers from within
AGEs in foods: Do they play a role in uremia?
Volume 87, Issue 1, Pages (January 2015)
The global challenge of chronic kidney disease
Volume 61, Issue 2, Pages (February 2002)
Volume 81, Issue 8, Pages (April 2012)
Volume 65, Issue 3, Pages (March 2004)
Mediterranean diets: are they practical in the Western world?
Volume 64, Issue 2, Pages (August 2003)
Daily nocturnal home hemodialysis
Wei-Teing Chen, Horng-Chin Yan, Fu-Chiu Yu  Kidney International 
Nanocrystals seed calcification in more ways than one
End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?  Mustafa Arici, John Walls  Kidney International 
Volume 72, Issue 2, Pages (July 2007)
The Danish Renal Biopsy Register
Volume 80, Issue 10, Pages (November 2011)
Elevated plasma F2-isoprostanes in patients on long-term hemodialysis
Volume 80, Issue 10, Pages (November 2011)
Volume 56, Pages S28-S30 (July 1999)
The Biological Role of Inflammation in Atherosclerosis
Is complement a target for therapy in renal disease?
James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD 
Volume 75, Issue 7, Pages (April 2009)
Volume 54, Issue 4, Pages (October 1998)
Antioxidant therapy in hemodialysis patients: a systematic review
Hemodialysis access failure: a call to action—revisited
Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge?  Ellen G. Neven, Marc E. De Broe, Patrick.
Volume 74, Issue 10, Pages (November 2008)
Impaired Lung Function and Risk for Stroke
Niamh E. Kieran, Paola Maderna, Catherine Godson  Kidney International 
Peter Stenvinkel, Olof Heimbürger, Catherine H. Tuck, Lars Berglund 
Presentation transcript:

Volume 62, Issue 5, Pages 1524-1538 (November 2002) The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia  Jonathan Himmelfarb, Peter Stenvinkel, T. Alp Ikizler, Raymond M. Hakim  Kidney International  Volume 62, Issue 5, Pages 1524-1538 (November 2002) DOI: 10.1046/j.1523-1755.2002.00600.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 The blind men and the elephant. Poem by John Godfrey Saxe (Cartoon originally copyrighted by the authors; G. Renee Guzlas, artist). Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Potential mechanisms for the role of oxidatively-modified low-density lipoprotein (LDL) in atherogenesis. Endothelial cells, vascular smooth muscle cells, or macrophages may catalyze the oxidative modification of circulating LDL leading to: (I) recruitment of circulating monocytes; (II) macrophage “trapping” in the vessel intima; (III) enhanced uptake of oxidized LDL by resident macrophages leading to foam cell formation; and (IV) endothelial cell destruction as a result of oxidized LDL toxicity (reprinted with permission from Quinn MT et al, Proc Natl Acad Sci USA, 82:5949–5953, 1985). Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Pathways of oxidant generation by activated leukocytes. Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Biochemistry of oxidant stress biomarkers. (A) Oxidation of tyrosine residues. (B) F2-isoprostane generation from arachidonic acid via free radicals. (C) Generation of reactive aldehydes (carbonyls). (D) Amino acid thiol group oxidation. (E) DNA oxidation. Abbreviations are: HOCL, hypochlorous acid; MPO, myeloperoxidase; CML, carboxymethyllysine; HNE, hydroxynonenal. Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 Elevated plasma protein 3-chlorotyrosine, a specific biomarker of myeloperoxidase-catalyzed oxidation, in hemodialysis patients. (Adapted with permission from Himmelfarb et al, Free Radical Biology & Medicine 31:1163–1169, 2001.) Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 6 Plasma protein thiol group oxidation (A) and carbonyl formation (B) in patients with chronic kidney disease and hemodialysis patients, demonstrating that plasma protein oxidation develops in renal disease well before ESRD. (Adapted with permission from Himmelfarb et al, Kidney Int 58:2571–2578, 2000.) Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 7 The malnutrition inflammation syndrome tips the redox balance toward oxidative stress and cardiovascular disease. Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 8 Major end points of the SPACE Study. Symbols are: () placebo; (▪) vitamin E. (Adapted with permission from Boaz et al, Lancet 356:1213–1218, 2000.) Kidney International 2002 62, 1524-1538DOI: (10.1046/j.1523-1755.2002.00600.x) Copyright © 2002 International Society of Nephrology Terms and Conditions